L-2-Hydroxyglutarate remodeling of the epigenome and epitranscriptome creates a metabolic vulnerability in kidney cancer models

MLA

Kundu, Anirban, et al. “L-2-Hydroxyglutarate Remodeling of the Epigenome and Epitranscriptome Creates a Metabolic Vulnerability in Kidney Cancer Models.” Journal of Clinical Investigation, vol. 134, no. 13, July 2024. EBSCOhost, https://doi.org/10.1172/JCI171294.

APA

Kundu, A., Brinkley, G. J., Nam, H., Karki, S., Kirkman, R., Shim, M. P., Widden, H., Liu, J., Heidarian, Y., Mahmoudzadeh, N. H., Absher, A. J. F., Ding, H.-F., Crossman, D. K., Placzek, W. J., Locasale, J. W., Rakheja, D., McConathy, J. E., Ramachandran, R., Bae, S., … Sudarshan, S. (2024). L-2-Hydroxyglutarate remodeling of the epigenome and epitranscriptome creates a metabolic vulnerability in kidney cancer models. Journal of Clinical Investigation, 134(13). https://doi.org/10.1172/JCI171294

Chicago

Kundu, Anirban, Garrett J. Brinkley, Hyeyoung Nam, Suman Karki, Richard Kirkman, Madhuparna PandiEunHee Shim, Hayley Widden, et al. 2024. “L-2-Hydroxyglutarate Remodeling of the Epigenome and Epitranscriptome Creates a Metabolic Vulnerability in Kidney Cancer Models.” Journal of Clinical Investigation 134 (13). doi:10.1172/JCI171294.